Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(PWRM, CYTR, FMER, JKHY, CLNO) Stock Report from Stock-PR.com

<p align="center">Stock-PR Reporting</p>
<p align="center"><a title="Stock-PR website" href="stock-pr.com&quot; target="_blank"><img class="alignnone size-full wp-image-2414" title="stockpr_logo-site" alt="stockpr_logo-site" src="stock-pr.com/img/stockpr_logo-site.jpg&quot; /></a></p>
<p align="center"> </p>
<p align="center"><strong><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="pennyomega.com/?page_id=835&quot;></a></strong></p>
<p align="center"><strong><span style="COLOR: black">FREE Daily Stock Alerts From Stock-PR.com</span></strong></p>
<p style="TEXT-ALIGN: center"> </p>
<p align="center"><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="stock-pr.com/?page_id=1085&quot;></a></p>
<p align="center"><span style="COLOR: black"><strong><span style="COLOR: black"><strong><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><a title="stock-pr sign up" href="stock-pr.com/signup&quot; target="_blank"><img height="90" alt="chartstockalert" src="pennyomega.com/img/chartstockalert.jpg&quot; width="360" /></a></span></span></strong></span></strong></span></p>
<p align="center"> </p>
<p align="center"> </p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong><img style="WIDTH: 176px; HEIGHT: 76px" height="63" alt="power3" hspace="0" src="pennyomega.com/img/power3.png&quot; width="152" align="bottom" border="0" /> Power3 Medical Products, Inc. (OTC:PWRM)<br /></strong><br />
The NuroPro Blood Test is Power3's medical diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.<br />
<br />
Parkinson's disease is a disorder of the central nervous system, which includes the brain and spinal cord, and controls everything you do, including moving. A person with Parkinson's disease gradually loses the ability to totally control body movements. In a person with Parkinson's disease, there nerve cells are damaged. These nerve cells make and use a brain chemical called dopamine to send messages to other parts of the brain to coordinate body movements.</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong>Power3 Medical Products, Inc.</strong> is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.<br />
<br />
Please visit Power3 Medical Products, Inc website</font> <a href="www.power3medical.com&quot;><font color="black">www.power3medical.com&lt;/font></a><font color="black">.<br />
<br />
**********************************<br />
<br />
<strong>CytRx Corporation (Nasdaq:CYTR)</strong> reported financial results for the three months ended March 31, 2011, and provided a business update. CytRx reported a net loss for the first quarter of 2011 of $6.3 million, or $0.06 per share, based on 109.2 million weighted average shares outstanding. The 2011 first quarter net loss included a recognized gain of $0.6 million resulting from the warrant derivative liabilities related to warrants issued in July 2009 being marked to market each quarter. The Company reported a net loss for the first quarter of 2010 of $0.6 million, or $0.01 per share, based on 108.9 million weighted average shares outstanding. The 2010 first quarter included a $3.8 million gain on the sales of shares of common stock in RXi Pharmaceuticals Corporation (Nasdaq:RXII - News) and $0.1 million on the valuation of warrant derivative liabilities related to warrants issued in July 2009. The Company's cash used in operating activities was approximately $3.7 million for the first quarter of 2011. Research and development (R&amp;D) expenses were $4.8 million for first quarter of 2011, compared with $2.0 million for first quarter of 2010. This increase resulted from the expansion of the Company's oncology clinical development programs.<br />
<br />
CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics, specializing in oncology.<br />
<br />
*************************************<br />
<br />
<strong>FirstMerit Corporation (Nasdaq:FMER)</strong> reported first quarter 2011 net income of $27.6 million, or $0.25 per diluted share. This compares with $27.0 million, or $0.25 per diluted share, for the fourth quarter of 2010 and $15.4 million, or $0.18 per diluted share, for the first quarter 2010. Returns on average common equity ("ROE") and average assets ("ROA") for the first quarter 2011 were 7.37% and 0.78%, respectively, compared with 7.04% and 0.74% for the fourth quarter of 2010 and 5.71% and 0.55% for the first quarter 2010. Net interest margin was 4.00% for the first quarter of 2011 compared with 4.14% for the fourth quarter of 2010 and 3.72% for the first quarter of 2010. The decline in net interest margin compared with the prior quarter was a result of declining average loan balances in the covered loan portfolio. The decline in the covered loan portfolio is to be expected as there were no new acquisitions of loans subject to loss share agreements after the quarter ended June 30, 2010.<br />
<br />
FirstMerit Corporation operates as the bank holding company for FirstMerit Bank, N.A. that provides a range of banking, fiduciary, financial, insurance, and investment services to corporate, institutional, and individual customers in northern and central Ohio, and western Pennsylvania.<br />
<br />
*************************************<br />
<br />
<strong>Jack Henry &amp; Associates Inc. (Nasdaq:JKHY)</strong> announced its Board of Directors declared a regular quarterly cash dividend of $.105 per share. The cash dividend on its common stock, par value $.01 per share, is payable on June 2, 2011, to stockholders of record as of May 20, 2011. At May 6, 2011, there were 86,745,546 shares of the common stock outstanding.<br />
<br />
Jack Henry and Associates, Inc. (NYSE:JHA) provides integrated computer systems and services for in-house and outsourced data processing to commercial banks, credit unions, and other financial institutions primarily in the United States.<br />
<br />
***************************************<br />
<br />
<strong><img class="alignnone size-full wp-image-16467" title="Clean" style="WIDTH: 250px; HEIGHT: 64px" height="64" alt="clno_logo_250x64" hspace="0" src="crwefinance.com/img/clno_logo_250x64.jpg&quot; width="250" align="bottom" border="0" /> Cleantech Transit Inc. (OTCPK:CLNO)<br /></strong><br />
<strong>Cleantech Transit Inc</strong>. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (</font><a href="www.phoenixenergy.net&quot;><font color="black">phoenixenergy.net&lt;/font></a><font color="black">). This project can generate shareholder returns as well benefit the Company's manufacturing clients worldwide. Cleantech Transit Inc. is in the business of producing and conserving power. It produces and sells clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind.<br />
<br />
Biomass energy is gaining popularity as a valuable energy supplement and is being acknowledged for its capability to help counteract many environmental problems facing us today. The controversy surrounding global warming, utilization of biomass energy has been noticed for its ability to inhibit increases in carbon dioxide and decreases in toxic pollutant concentrations in the atmosphere. Its high potential to alleviate stresses on the environment due to unnecessary waste of biomass residues, of usable croplands, of jobs that could be created, of total energy overall has been identified and should be recognized for its value to socioeconomic trends as well as environmental ones.</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong>Cleantech Transit Inc.</strong> recently announced that funding to be provided to Phoenix Energy for the commercialization of a 500 Kilowatt biomass gasification plant should be eligible to apply for a renewable energy cash back incentive program offered by the U.S. Federal Government. Once the final interconnect process and applications are complete the grant should be received within 60 days. The 5-year grant vesting period, means all parties must remain owner of record for that length of time, underscoring Cleantech and its partners' commitment to this project and the host community. The U.S. Treasury's cash grant program was created to provide funding, in lieu of tax credits, for the development of clean energy projects and clean tech jobs nationwide. The Merced facility has already employed several individuals, both for the construction phase and subsequent plant operations once in service.As Company announced, the full commercial operation of the first plant is expected to be completed during the second quarter of 2011.<br />
<br />
Please visit Cleantech Transit, Inc. website</font> <a href="www.cleantechtransitinc.com&quot;><font color="black">cleantechtransitinc.com&lt;/font></a><font color="black">.</font><br /></span></span></span></span></p>
<p align="center"> </p>
<p align="center"> </p>
<p align="center">**************************************************************</p>
<p align="center"><strong>THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!</strong></p>
<p><strong><font color="blue"><font color="red">Disclaimer:</font> Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (<font color="red">Read more at <a href="stock-pr.com/?page_id=40&quot; target="_blank"><font color="red">stock-pr.com/disclaimer&lt;/font></a></font>).</font></strong><span style="COLOR: red"><span style="COLOR: red"><strong><font color="blue">Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.</font><font color="red">Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM). Crown Equity Holdings Inc. (OTCPK:CRWE) anticipates receiving 2,000,000 shares of 144 restricted stocks from the company for 12 months of advertisement services for Cleantech Transit, Inc. (OTCPK:CLNO).</font></strong></span></span></p>
<p align="center">Sign Up For Free Stock Alerts At <a href="stock-pr.com/signup&quot; target="_blank">stock-pr.com/signup&lt;/a></p>
<p align="center"><a href="www.crownequityholdings.com&quot; target="_blank"><img alt="stock-pr.com/img/stock-pr_buscard.jpg&quot; src="stock-pr.com/img/stock-pr_buscard.jpg&quot; /></a></p>